Anneke J.J. Rampen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anneke J.J. Rampen has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Denes L.J. Tavy
Department of Neurology, HagaZiekenhuis, Leyweg 275, 2545 CH Den Haag, The Netherlands
1 shared publicationI Van Heuvel
1 shared publicationJ L M Jongen
1 shared publicationM Scheltens-De Boer
1 shared publication- Martin J. van Den Bent
The Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
1 shared publication P Sonneveld
1 shared publication
Latest Publications
- 1 April 2013
- Vol. 71 (3) , 128-33
Bortezomib-induced polyneuropathy.
Peripheral neuropathy is a frequent side effect of bortezomib chemotherapy. Relatively little is known about the clinical characteristics of this neuropathy, especially with respect to pain. Our aim was to describe the clinical characteristics and course of bortezomib-induced polyneuropathy. This is a retrospective cohort study of 39 patients diagnosed with bortezomib-induced polyneuropathy. Pain is the most prominent symptom and 14 of 39 patients suffered from severe pain. More than 50% of our patients used analgesics due to moderate or severe pain. We found no correlation between severity of symptoms of bortezomib-induced polyneuropathy and cumulative dose or dose intensity of bortezomib. Nerve conduction studies did not correlate well with symptom severity. Dose reduction or discontinuation of treatment reduced severity in most cases. Painful polyneuropathy is a frequent, dose-limiting side effect of bortezomib with a relatively good prognosis. Careful neurological monitoring of symptoms and timely dose adjustment is important.
- 1 April 2013
- Vol. 71 (3) , 128-33
Bortezomib-induced polyneuropathy.
Peripheral neuropathy is a frequent side effect of bortezomib chemotherapy. Relatively little is known about the clinical characteristics of this neuropathy, especially with respect to pain. Our aim was to describe the clinical characteristics and course of bortezomib-induced polyneuropathy. This is a retrospective cohort study of 39 patients diagnosed with bortezomib-induced polyneuropathy. Pain is the most prominent symptom and 14 of 39 patients suffered from severe pain. More than 50% of our patients used analgesics due to moderate or severe pain. We found no correlation between severity of symptoms of bortezomib-induced polyneuropathy and cumulative dose or dose intensity of bortezomib. Nerve conduction studies did not correlate well with symptom severity. Dose reduction or discontinuation of treatment reduced severity in most cases. Painful polyneuropathy is a frequent, dose-limiting side effect of bortezomib with a relatively good prognosis. Careful neurological monitoring of symptoms and timely dose adjustment is important.
- 9 June 2011
- Published by Wiley in Muscle & Nerve
- Vol. 44 (1) , 128-130
Ultrasound‐guided steroid injection to treat mild ulnar neuropathy at the elbow
There exists no “gold standard” in the treatment of ulnar neuropathy at the elbow (UNE). We treated 7 patients with mild UNE using a local steroid injection with ultrasonographic monitoring. At clinical follow‐up after 6 weeks, 4 patients had improved, 2 were stable, and 1 reported an increase in symptoms. Ultrasound‐guided steroid injection in mild UNE is safe and could be effective. Further investigation is needed to prove its efficacy. Muscle Nerve 44: 128–130, 2011.
- 9 June 2011
- Published by Wiley in Muscle & Nerve
- Vol. 44 (1) , 128-130
Ultrasound‐guided steroid injection to treat mild ulnar neuropathy at the elbow
There exists no “gold standard” in the treatment of ulnar neuropathy at the elbow (UNE). We treated 7 patients with mild UNE using a local steroid injection with ultrasonographic monitoring. At clinical follow‐up after 6 weeks, 4 patients had improved, 2 were stable, and 1 reported an increase in symptoms. Ultrasound‐guided steroid injection in mild UNE is safe and could be effective. Further investigation is needed to prove its efficacy. Muscle Nerve 44: 128–130, 2011.